On Monday, Verastem Inc (NASDAQ: VSTM) was -8.73% drop from the session before settling in for the closing price of $7.79. A 52-week range for VSTM has been $4.01 – $11.24.
Annual sales at Healthcare sector company grew by 31.36% over the past five years. When this article was written, the company’s average yearly earnings per share was at 14.82%. With a float of $65.21 million, this company’s outstanding shares have now reached $66.75 million.
Verastem Inc (VSTM) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Verastem Inc stocks. The insider ownership of Verastem Inc is 13.42%, while institutional ownership is 79.24%. The most recent insider transaction that took place on Dec 24 ’25, was worth 629. In this transaction Chief Financial Officer of this company sold 80 shares at a rate of $7.86, taking the stock ownership to the 109,758 shares. Before that another transaction happened on Dec 16 ’25, when Company’s Director sold 592 for $9.14, making the entire transaction worth $5,411. This insider now owns 101,147 shares in total.
Verastem Inc (VSTM) Latest Financial update
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.6 earnings per share (EPS) during the time that was better than consensus figure (set at -0.74) by 0.14. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.54 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 14.82% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 37.85% during the next five years compared to 31.36% growth over the previous five years of trading.
Verastem Inc (NASDAQ: VSTM) Trading Performance Indicators
You can see what Verastem Inc (VSTM) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.55. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 40.02.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.26, a number that is poised to hit -0.52 in the next quarter and is forecasted to reach -1.79 in one year’s time.
